Abstracts tagged "laboratory tests and rheumatoid arthritis (RA)"

Abstract Number: 2467 • 2018 ACR/ARHP Annual Meeting
RAPID3 Is Elevated in 93% of Treatment-Naïve Rheumatoid Arthritis (RA) Patients at Initial Visit Compared to 49% for Erythrocyte Sedimentation Rate (ESR) and 44% for C-Reactive Protein (CRP)
Mariam Riad, Jacquelin R. Chua, Isabel Castrejón and Theodore Pincus, Division of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Quantitative measures to assess and monitor patients with rheumatoid arthritis (RA) traditionally have been laboratory tests, such as erythrocyte sedimentation rate (ESR) and C-reactive…
Abstract Number: 2031 • 2017 ACR/ARHP Annual Meeting
Online Viewing of Labs in RA Patients Is Not Associated with Clinically Significant Change in ESR over 18 Months Compared to Non-Viewers
Sheryl Mascarenhas¹, Shuvro Roy², April Pinto² and Preeta Gupta², ¹Rheumatology, The Ohio State University, Columbus, OH, ²The Ohio State University, Columbus, OH
Background/Purpose: As part of passage of the Affordable Care Act in 2010, Meaningful Use Core Measures were outlined to improve electronic medical record (EMR)…
Abstract Number: 491 • 2016 ACR/ARHP Annual Meeting
Anti-Citrullinated Peptide Antibodies Testing Rate over Time in Newly Diagnosed RA Patients – Data from Three Administrative Claims Databases (2007–2014)
E Alemao, Z Guo and L Burns, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Current clinical guidelines recommend testing for anti-citrullinated protein antibodies (ACPA) at the time of RA diagnosis.1 However, there is a lack of information about…
Abstract Number: 2676 • 2015 ACR/ARHP Annual Meeting
Is It Useful to Determine All Rheumatoid Factors Isotypes to Enhance Rheumatoid Arthritis Detection? a Clinical Laboratory Perspective
Alejandro Garza-Alpirez¹, Mario Alberto Garza-Elizondo², David Vega-Morales², Cassandra Skinner-Taylor², Ricardo Ramírez³, Roberto Negrete-López⁴, Jorge Esquivel-Valerio², Miguel Villarreal-Alarcon² and Andrés Mendiola¹, ¹Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario " Dr. José Eleuterio González". Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Rheumatology, Hospital Universitario, UANL., Monterrey, Mexico, ⁴Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario, Monterrey, Mexico
Background/Purpose: Rheumatoid arthritis (RA) diagnosis includes determination of autoantibodies and, their presence can represents 33% (2/6) to 50% (3/6) of the 2010 ACR/EULAR classification criteria…
Abstract Number: 1519 • 2014 ACR/ARHP Annual Meeting
Implementation of an Acid Dissociation Procedure for Immunogenicity Detection in Patients Treated with ANTI-TNF Drugs
Francisca Llinares-Tello¹, Jose Rosas², José M. Senabre-Gallego³, Gregorio Santos-Soler³, Carlos Santos-Ramirez⁴, Esteban Salas-Heredia³, Xavier Barber⁵, Juan Molina¹, Catalina Cano³, Ana Pons³ and Group Aire-MB³, ¹Laboratory, Hospital Marina Baixa, Villajoyosa, Spain, ²Rheumatology, Hospital Marina Baixa. Villajoyosa, Villajoyosa, Spain, ³Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ⁴Rheumatology, Hospital Marina Salud, Denia, Spain, ⁵Universidad Miguel Hernández, CIO, Elche, Spain
Background/Purpose To evaluate the application of an acid dissociation procedure in monitoring patients with subtherapeutic serum concentrations of infliximab (IFX), adalimumab (ADL) and etanercept (ETN),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].